glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research glp-1_analogs [TUSOM | Pharmwiki]
Description
GLP-1 can directly bind to the receptors on the surface of -cells in the pancreas, inhibiting the secretion of glucagon from these cells
![glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
Brown had first met Creutzfeldt at a meeting in Davos, Switzerland, who encouraged him to think about GIP's potential clinical applications
![glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research glp-1_analogs [TUSOM | Pharmwiki]](https://images.ctfassets.net/4f3rgqwzdznj/6EvbT3zOercHcdXIiTKfAw/0e5c4f72a7cc3d67aad2435c7c4e33cc/GLP-1_Receptor_Agonist_for_Diabetes.png)
2017;5:e000429
![glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research glp-1_analogs [TUSOM | Pharmwiki]](https://medrac.web.unc.edu/wp-content/uploads/sites/22579/2025/03/AD_4nXecYXk7BfwC6adHH808V596nosg2pYs4yDUs6TBM_JMmx7_pGkjqpOwyHWy2Rj2TdJt-SPUxEipYqiO5CftWX-CaAm_fXRTU6dpEuJkuUscaLenZ1xGLWDdf_XVsOIjaZt08BpA4A.png)
The median time elapsed from the earliest patent filing date within a given product to the expiration date of the last-to-expire patent or exclusivity on that product was 31.9 years (IQR: 29.9-36.6)
![glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research glp-1_analogs [TUSOM | Pharmwiki]](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c31/8085572/4a88427f7931/gr3.jpg)
Pereira, S
![glp-1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research glp-1_analogs [TUSOM | Pharmwiki]](https://static.elsevier.es/multimedia/20132514/0000004300000004/v3_202505300603/S2013251423001475/v3_202505300603/en/main.assets/gr1.jpeg)